Introduction {#s1}
============

Prostate cancer is the most frequent and second most lethal cancer in men in the United States [@pone.0051680-Jemal1]. There is growing evidence that innate immunity and inflammation may play a role in prostate and other cancers [@pone.0051680-Coussens1], [@pone.0051680-deVisser1], [@pone.0051680-deVisser2]. Chronic inflammation could contribute to prostate cancer through several biological processes: the mutagenesis caused by oxidative stress; the remodeling of the extracellular matrix; the recruitment of immune cells, fibroblasts, and endothelial cells; or the induction of cytokines and growth factors contributing to a proliferative and angiogenic environment [@pone.0051680-Coussens1], [@pone.0051680-deVisser1], [@pone.0051680-Hanahan1].

Compelling evidence supports a role for genes involved in the innate immunity and inflammation pathway in prostate cancer risk. Several genes harboring single nucleotide polymorphisms (SNPs) associated with prostate cancer risk have been identified, including: the pattern recognition receptors *MSR1*, *TLR1*, *TLR4*, *TLR5*, *TLR6*, and *TLR10* [@pone.0051680-Chen1], [@pone.0051680-Lindmark1], [@pone.0051680-Miller1], [@pone.0051680-Rennert1], [@pone.0051680-Seppala1], [@pone.0051680-Sun1], [@pone.0051680-Sun2], [@pone.0051680-Xu1], [@pone.0051680-Xu2], [@pone.0051680-Xu3], [@pone.0051680-Zheng1]; the antiviral gene *RNASEL* [@pone.0051680-Rennert1], [@pone.0051680-Casey1], [@pone.0051680-Nakazato1], [@pone.0051680-NoonanWheeler1], [@pone.0051680-Rennert2], [@pone.0051680-Wang1]; the cytokines *MIC1*, *IL8*, *TNFα*, and *IL1RN* [@pone.0051680-Xu1], [@pone.0051680-Lindmark2], [@pone.0051680-Lindmark3], [@pone.0051680-McCarron1], [@pone.0051680-Oh1], [@pone.0051680-Wu1]; and the pro-inflammatory gene *COX-2* [@pone.0051680-Cheng1], [@pone.0051680-Panguluri1], [@pone.0051680-Reese1], [@pone.0051680-Shahedi1]. However, most of the previous studies have focused on individual SNPs or genes and very little is known about the impact of the overall innate immunity and inflammation pathway on developing more advanced prostate cancer.

Moreover, advanced prostate cancer cases have a higher public health burden than less advanced cases. Thus, identifying the components of the innate immunity and inflammatory process that increase the risk of advanced prostate cancer is of major importance.

To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 SNPs, located in 46 innate immunity and inflammation genes, with advanced prostate cancer risk. We undertook a comprehensive approach evaluating the association between disease risk and SNPs-sets pooled across the whole pathway, sub-pathways, and each gene, as well as individual SNPs.

Materials and Methods {#s2}
=====================

Study Population {#s2a}
----------------

The case sample comprised 494 men with newly diagnosed, histologically confirmed prostate cancer, having either a Gleason score ≥7, a clinical stage ≥ T2c, or a serum Prostate Serum Antigen (PSA) at diagnosis \>10 recruited from the major medical institutions in Cleveland, Ohio (Cleveland Clinic Foundation, University hospitals of Cleveland, and their affiliates) [@pone.0051680-DAmico1]. The control sample comprised 536 men frequency matched to cases by age (within 5 years), ethnicity, and medical institution, who underwent standard annual exams at the major medical institutions in Cleveland, and who did not have a previous history of non-skin cancer. The PSA was measured and found elevated in two controls. Further investigations lead us to reclassify them as advanced cases of prostate cancer, leaving us with a total of 494 advanced prostate cancer cases and 536 controls used here in our analyses. Approval for this study was obtained from the University Hospitals of Cleveland Institutional Review Board and the Cleveland Clinic Foundation Institutional Review Board, and written informed consent was obtained from all study participants. More details about this study population have been previously described [@pone.0051680-Cheng1], [@pone.0051680-Reese1], [@pone.0051680-Cheng2], [@pone.0051680-Hardin1], [@pone.0051680-Liu1], [@pone.0051680-Ross1], [@pone.0051680-Rybicki1].

SNP Selection, Genotyping and Quality Control {#s2b}
---------------------------------------------

We selected for study 46 candidate genes coding for proteins involved in innate immunity and inflammation, and further grouped these into 6 relevant biological sub-pathways using a previously proposed and published classification [@pone.0051680-Loza1]. These sub-pathways were: 1) cytokine signaling (26 genes), 2) eicosanoid signaling (1 gene, i.e. *COX-2*), 3) extracellular pattern recognition (8 genes), 4) intracellular antiviral molecules (4 genes), 5) nuclear kappa-light chain-enhancer or activated B cell (NFKB) signaling (5 genes), and 6) selenoproteins (2 genes). The genes *SELS* and *SEP15* coding for selenoproteins were included because of their potential role in the control of the inflammatory response through regulation of cytokine production [@pone.0051680-Kaushal1].

All SNPs located within and 2 kb upstream and 1 kb downstream of the sequence of the 46 candidate genes were identified through the International HapMap Project ([www.hapmap.org](http://www.hapmap.org)) and the Genome Variation Server (SeattleSNPs) (<http://gvs.gs.washington.edu/>). Then, tagging SNPs were selected using the multimarker test criteria in the Tagger software program [@pone.0051680-deBakker1] to capture all common SNPs (minor allele frequency, MAF \>0.05) with an r^2^≥0.8 across each candidate gene among European ancestry populations, forcing SNPs that are missense, non-synonymous and previously associated with prostate cancer to be included. Only one missense SNP was included for the genes *TLR3* and *IL6R*.

Moreover, 39 ancestry informative markers (AIMs) [@pone.0051680-Shriver1] were genotyped and principal component analysis was used to estimate genetic ancestry and account for population stratification [@pone.0051680-Price1]. The first principal component of this analysis distinguished African Americans from Caucasians and was used as an estimate of genetic ancestry.

Genotyping of the 330 SNPs was done on DNA extracted from blood samples using either the Illumina 500G BeadStation coupled with the GoldenGate assay, or the Applied Biosystems Taqman assay. Further quality control procedures were done separately for each of the two platforms and for each of the two ethnic groups (African-Americans and Caucasians). Ten SNPs that had a call rate \<0.90, deviated from the expected Hardy-Weinberg proportions in both ethnic groups (P\<0.01), or had a MAF below 0.01 in both ethnic groups were excluded. Individuals who had a call rate \<0.90 were also excluded. After the quality control procedure, the data in the case-control sample used to test for association with risk of advanced prostate cancer included 320 tagging SNPs ([Table S1](#pone.0051680.s001){ref-type="supplementary-material"}) and 39 AIMs.

Statistical Analysis {#s2c}
--------------------

To analyze the whole set of 320 SNPs together, or sets of SNPs grouped by sub-pathways or genes, we used the SNP-set kernel-machine association test (SKAT v0.62) [@pone.0051680-Wu2]. This method uses a logistic kernel-machine model, aggregating individual score test statistics of SNPs, and provides a global P-value for the set of variants tested that takes into account the joint effect of the SNPs in a given SNP-set and allows for incorporating the adjustment covariates: age, institution, and genetic ancestry. One advantage of SKAT over other pathway tests is that it adaptively finds the degrees of freedom of the test statistic in order to account for LD between genotyped SNPs. Assuming that each of the association coefficients for the *p* SNPs in a particular SNP-set (*β~Gp~*) independently follows an arbitrary distribution with mean 0 and variance *ψ*, testing the null hypothesis, *β~Gm~* = 0, is equivalent to testing *ψ* = 0 (*i.e.*, a variance-component test score done using the corresponding mixed model). For a case-control sample with *n* individuals sampled and *p* variants genotyped, **G** is the *n*×*p* matrix of genotypes, and **K** = **GG** ^T^ is an *n*×*n* linear kernel matrix, which defines the genetic similarity between all individuals for the *p* SNPs. The function that links each element of the matrix **K** to the genotypes **G** is the kernel function. To test for the association between the disease and the SNP-set, the variance-component score statistic Q follows a mixture of chi-square distributions.where, is the predicted mean of the vector of disease status values (**y**) under the null hypothesis, obtained by regressing **y** on the adjustment covariates only. For theses analyses, we used the linear kernel (equivalent to fitting the unconditional multivariate logistic regression) and the exact Davies method for computing p-values. Moreover, we tested for association of advanced prostate cancer risk with the 320 SNPs individually using unconditional multivariate logistic regression adjusting for age, institution, and genetic ancestry. Odds ratios (ORs), 95% confidence intervals (95% CI) and P-values were estimated using both co-dominant and log-additive models.

To adjust for genetic ancestry in all analyses, we included the first principal component of the principal component analysis of the 39 AIMs as covariate. Moreover, to identify SNPs with potential opposite effects in African Americans and Caucasians, we also stratified all analyses by reported ethnicity. Our strategy evaluated disease risk association at multiple levels of SNP groupings (whole set, sub-pathways, genes, and individual SNPs). To account for the multiple tests done while incorporating the correlation between SNPs and genotype coding, we used a permutation procedure to obtain the empirical distribution of statistical tests under the null hypothesis of no association with the set of SNPs or SNP. Then for each level of SNP groupings, we calculated a family-wise error rate by comparing the P-value of each test to the distribution of the minimum P-values obtained from 1000 permuted data sets. Reported P-values are two-sided and analyses were done using R v2.13.1 [@pone.0051680-R1].

Results {#s3}
=======

Study Subject Characteristics {#s3a}
-----------------------------

The case-control sample included 1,030 subjects whose average age at diagnosis or recruitment was 65.87 (SD: 8.46) years, and was comprised of 194 African Americans (18.8%) and 836 Caucasians (81.2%). Age and ethnicity were similarly distributed in advanced prostate cancer cases and controls ([Table 1](#pone-0051680-t001){ref-type="table"}).

10.1371/journal.pone.0051680.t001

###### Study characteristics of the advanced prostate cancer cases and controls.

![](pone.0051680.t001){#pone-0051680-t001-1}

                                                                                       Cases   Controls   P-value of           
  ----------------------------------------------------------------------------------- ------- ---------- ------------ -------- -------------
  Age (year), mean (SD)                                                                65.90    (8.34)      65.85      (8.54)      0.91
  Ethnicity, *n* (%)                                                                                                           
  African American                                                                      90      (18.2)       104       (19.4)      0.68
  Caucasian                                                                             404     (81.8)       432       (80.6)  
  Prostate cancer in first degree relative, *n* (%)[b](#nt102){ref-type="table-fn"}                                            
  Negative                                                                              381     (77.3)       472       (88.9)   \<2×10^−16^
  Positive                                                                              112     (22.7)        59       (11.1)  
  PSA at diagnosis (ng/mL), mean (SD)                                                  14.38   (27.67)       1.74      (1.71)   \<2×10^−16^
  Categories of PSA at diagnosis, *n* (%)                                                                                      
  \<4.0                                                                                 25      (5.1)         --         --    
  4.0--9.9                                                                              249     (50.4)        --         --    
  10--19.9                                                                              152     (30.8)        --         --    
  20--49.9                                                                              53      (10.7)        --         --    
  \>50                                                                                  15      (3.0)         --         --    
  Gleason score, *n* (%)                                                                                                       
  ≤6                                                                                    74      (15.0)        --         --    
  3+4                                                                                   217     (43.9)        --         --    
  4+3 or ≥8                                                                             203     (41.1)        --         --    
  Clinical stage, *n* (%) [b](#nt102){ref-type="table-fn"}                                                                     
  T1                                                                                    306     (64.7)        --         --    
  T2a-T2b                                                                               127     (26.8)        --         --    
  T2c                                                                                   15      (3.2)         --         --    
  T3--T4                                                                                25      (5.3)         --         --    

P-values obtained using either a Student t-test (quantitative coding) or a Chi-square test (qualitative coding).

The sum of all categories does not add to the total due to missing data.

Association with Advanced Prostate Cancer Risk {#s3b}
----------------------------------------------

Taken together, the whole set of 320 SNPs in the innate immunity and inflammation pathway was significantly associated with advanced prostate cancer risk (P = 0.02). Of the 6 sub-pathways analyzed, the intracellular antiviral molecules and the extracellular pattern recognition sub-pathways were nominally associated with advanced prostate cancer risk (P = 0.02 for both) but not associated after correction for multiple testing (P = 0.12 and P = 0.11, respectively).

Interestingly, 4 genes in these 2 sub-pathways were also nominally associated with prostate cancer risk: *TLR1* and *TLR6* in the extracellular pattern recognition sub-pathway (P = 0.002 and P = 0.04, respectively), and *OAS1* and *OAS2* in the intracellular antiviral molecules sub-pathway (P = 0.015 and P = 0.019, respectively). In addition, *IFNGR1* in the cytokine signaling sub-pathway and *COX-2*, which is the sole member of the eicosanoid signaling sub-pathway represented in our data set, had nominal P-values of 0.006.and 0.044, respectively ([Table 2](#pone-0051680-t002){ref-type="table"}). However, none of these associations are robust to correction for multiple testing (P = 0.10 for the association with *TLR1*).

10.1371/journal.pone.0051680.t002

###### Association of the whole pathway, sub-pathways, and genes of innate immunity and inflammation with advanced prostate cancer risk.
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  SNP set                                                       SNP count                P-value                                                     
  ------------------------------------------------------------ ----------- ------------------------------------ ------------------------------------ ------------------------------------
  Inflammation and innate immunity                                 320                     0.02                                 0.29                                 0.01
  • Cytokine signaling (26 genes)                                  179                     0.44                                 0.33                                 0.57
  * IL10*                                                           8                      0.34                                 0.42                                 0.47
  * IL12RB2*                                                       11                      0.75                                 0.89                                 0.61
  * IL6R*                                                           1       --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}
  * IL18R1*                                                        16                      0.11                                 0.09                                 0.31
  * IL1B*                                                           4                      0.53                                 0.58                                 0.59
  * IL1RN*                                                          7                      0.42                                 0.50                                 0.51
  * IL12A*                                                          4                      0.12                                 0.66                                 0.13
  * TGFBR2*                                                        33                      0.75                                 0.22                                 0.78
  * IL2*                                                            5                      0.81                                 0.41                                 0.63
  * IL8*                                                            4                      0.18                                  1                                   0.17
  * IL12B*                                                          6                      0.45                                 0.59                                 0.46
  * IL13*                                                           4                      0.84                                 0.11                                 0.95
  * IL4*                                                            4                      0.41                                 0.23                                 0.60
  * IL5*                                                            1       --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}
  * IFNGR1*                                                         5                     0.006                                 0.16                                0.009
  * IL17*                                                           8                      0.41                                 0.56                                 0.21
  * TNF/LTA*                                                       11                      0.72                                 0.44                                 0.92
  * TGFBR1*                                                         6                      0.49                                 0.40                                 0.52
  * IL18*                                                           8                     0.048                                 0.07                                 0.08
  * IFNG*                                                           6                      0.19                                 0.20                                 0.40
  * IL23A*                                                          1       --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}
  * IL12RB1*                                                        5                      0.57                                 0.45                                 0.41
  * MIC1*                                                           6                      0.94                                 0.10                                 0.51
  * TGFB1*                                                          4                      0.22                                 0.08                                 0.68
  * IFNGR2*                                                         9                      0.72                                 0.86                                 0.78
  * MIF*                                                            2                      0.36                                  1                                   0.23
  • Eicosanoid signaling (1 gene: *COX2*)                           9                      0.04                                 0.07                                 0.09
  • Extracellular pattern recognition (8 genes)                    56                      0.02                                 0.12                                 0.01
  * TLR5*                                                           7                      0.49                                 0.69                                 0.48
  * TLR1*                                                           7                     0.002                                 0.09                                0.004
  * TLR10*                                                          7                      0.18                                 0.35                                 0.07
  * TLR2*                                                           8                      0.63                                 0.28                                 0.37
  * TLR3*                                                           1       --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}   --[a](#nt103){ref-type="table-fn"}
  * TLR6*                                                           5                      0.04                                 0.04                                 0.04
  * MSR1*                                                          16                      0.37                                 0.09                                 0.36
  * TLR4*                                                           5                      0.11                                 0.05                                 0.19
  • Intracellular antiviral molecules (4 genes)                    40                      0.02                                 0.71                                 0.01
  * RNASEL*                                                         7                      0.31                                 0.24                                 0.43
  * EIF2AK2*                                                       11                      0.79                                 0.41                                 0.44
  * OAS1*                                                           5                     0.015                                 0.92                                 0.01
  * OAS2*                                                          17                     0.019                                 0.79                                 0.01
  • NFKB[b](#nt104){ref-type="table-fn"} signaling (5 genes)       27                      0.32                                 0.04                                 0.48
  * NFKB1*                                                         10                      0.70                                 0.49                                 0.58
  * IKBKB*                                                          7                      0.18                                 0.46                                 0.13
  * CHUK*                                                           6                      0.14                                 0.07                                 0.28
  * RELA*                                                           2                      0.16                                 0.04                                 0.51
  * NFKBIA*                                                         2                      0.67                                 0.24                                 0.72
  • Selenoproteins (2 genes)                                        9                      0.67                                 0.93                                 0.44
  * SEP15*                                                          5                      0.37                                 0.74                                 0.21
  * SELS*                                                           4                      0.95                                 0.86                                 0.94

Genes with one SNP;

NFKB: nuclear kappa-light chain-enhancer or activated B cell.

The results of the individual SNP analyses supported the findings obtained with the sub-pathway and gene sets. Indeed, most of the SNPs having a nominal association P-value below 0.01, belong to *TLR1*, *TLR6*, *OAS1*, *OAS2* or *COX-2* ([Table 3](#pone-0051680-t003){ref-type="table"}). Moreover, many of the other SNPs in these genes have a p-value between 0.01 and 0.05 ([Table S2](#pone.0051680.s002){ref-type="supplementary-material"}). Interestingly, for all these SNPs, results indicate a protective effect of the minor allele with additive ORs between 0.73 and 0.77. But again, when correcting for multiple testing, these were no longer significant (P = 0.42 for the most significant association).

10.1371/journal.pone.0051680.t003

###### Association of SNPs with advanced prostate cancer risk (P-value \<0.01).
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  Gene (chromosome)       SNP        Overall    African Americans   Caucasians                                                     
  ------------------- ------------ ----------- ------------------- ------------ -------------------- -------- -------------------- ----------------
  *TLR1* (4)           rs5743551       AA            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       AG       0.75 (0.57, 0.99)     0.044      0.86 (0.11, 5.69)    0.876    0.73 (0.55, 0.97)        0.032
                                       GG       0.51 (0.34, 0.78)   **0.002**    0.52 (0.07, 3.35)    0.492    0.53 (0.32, 0.88)        0.014
                                    trend (G)   0.73 (0.60, 0.88)   **0.001**     0.64 (0.37, 1.1)    0.103     0.73 (0.59, 0.9)      **0.003**
  *OAS2* (12)          rs1058480       CC            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       CG       0.73 (0.56, 0.96)     0.026      1.44 (0.64, 3.29)    0.379     0.67 (0.5, 0.89)      **0.007**
                                       GG       0.54 (0.35, 0.82)   **0.005**    1.02 (0.12, 8.88)    0.988     0.5 (0.32, 0.78)      **0.002**
                                    trend (G)   0.73 (0.60, 0.89)   **0.001**    1.26 (0.65, 2.48)    0.495     0.7 (0.57, 0.85)    **3.8×10^−4^**
  *OAS2* (12)           rs15895        GG            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       GA       0.74 (0.57, 0.98)     0.034      1.44 (0.64, 3.29)    0.379    0.68 (0.51, 0.91)      **0.009**
                                       AA       0.54 (0.35, 0.82)   **0.005**    1.02 (0.12, 8.88)    0.988     0.5 (0.32, 0.78)      **0.002**
                                    trend (A)   0.74 (0.61, 0.89)   **0.002**    1.26 (0.65, 2.48)    0.495     0.7 (0.57, 0.85)    **4.6×10^−4^**
  *TLR1* (4)           rs4833095       AA            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       AG       0.76 (0.57, 1.00)     0.053       0.82 (0.1, 5.49)    0.840    0.75 (0.57, 1.01)        0.0545
                                       GG       0.53 (0.35, 0.81)   **0.003**     0.6 (0.07, 3.88)    0.586     0.5 (0.3, 0.83)       **0.008**
                                    trend (G)   0.74 (0.60, 0.90)   **0.002**    0.74 (0.42, 1.27)    0.274     0.73 (0.59, 0.9)      **0.003**
  *TGFBR1* (9)         rs10512263      AA            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       AG       2.05 (1.35, 3.16)   **0.001**    5.37 (1.28, 36.55)   0.0382   1.88 (1.21, 2.95)        0.006
                                       GG       0.92 (0.18, 4.20)     0.912              --             --     0.92 (0.18, 4.21)        0.914
                                    trend (G)   1.73 (1.19, 2.54)   **0.004**    5.37 (1.28, 36.55)   0.020    1.59 (1.08, 2.36)        0.019
  *TLR6* (4)           rs5743795       GG            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       GA       0.73 (0.55, 0.97)     0.027       1.3 (0.44, 3.89)    0.634     0.7 (0.52, 0.93)        0.016
                                       AA       0.53 (0.25, 1.05)     0.074              --             --     0.52 (0.25, 1.03)        0.068
                                    trend (A)   0.73 (0.58, 0.92)   **0.007**     1.3 (0.44, 3.89)    0.634     0.71 (0.56, 0.9)      **0.004**
  *TLR6* (4)           rs5743794       GG            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       GA       0.73 (0.55, 0.97)     0.029       1.3 (0.44, 3.91)    0.627     0.7 (0.52, 0.94)        0.017
                                       AA       0.53 (0.26, 1.05)     0.075              --             --     0.52 (0.25, 1.04)        0.070
                                    trend (A)   0.73 (0.58, 0.92)   **0.008**     1.3 (0.44, 3.91)    0.627     0.71 (0.56, 0.9)      **0.005**
  *TLR1* (4)           rs5743618       GG            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       GT       0.81 (0.61, 1.09)      0.15              --             --     0.79 (0.58, 1.06)        0.117
                                       TT       0.55 (0.37, 0.86)   **0.007**            --             --     0.55 (0.34, 0.89)        0.015
                                    trend (T)   0.76 (0.63, 0.93)   **0.008**            --             --     0.76 (0.61, 0.94)      **0.010**
  *OAS2* (12)          rs1293767       GG                                             1 (Ref)           --          1 (Ref)               --
                                       GC       0.70 (0.54, 0.92)     0.012      1.22 (0.54, 2.74)    0.632    0.65 (0.49, 0.87)      **0.004**
                                       CC       0.67 (0.43, 1.05)     0.080      1.17 (0.05, 30.16)   0.914    0.64 (0.41, 1.01)        0.059
                                    trend (C)   0.77 (0.64, 0.94)   **0.010**    1.18 (0.58, 2.44)    0.643    0.75 (0.61, 0.92)      **0.005**
  *COX-2* (1)          rs2745557       GG            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       GA       0.68 (0.51, 0.90)   **0.007**    0.67 (0.33, 1.32)    0.249    0.67 (0.49, 0.91)        0.011
                                       AA       0.77 (0.36, 1.62)     0.496              --             --     0.93 (0.42, 2.04)        0.862
                                    trend (A)   0.74 (0.58, 0.94)     0.013       0.57 (0.3, 1.05)    0.074    0.77 (0.59, 0.99)        0.042
  *OAS1* (12)          rs2285934       CC            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       CA       0.64 (0.49, 0.85)   **0.002**    0.39 (0.17, 0.86)    0.021     0.7 (0.52, 0.95)        0.022
                                       AA       0.71 (0.48, 1.03)     0.074      0.83 (0.35, 1.91)    0.653    0.62 (0.39, 0.96)        0.033
                                    trend (A)   0.79 (0.66, 0.95)     0.014      0.97 (0.64, 1.47)    0.880    0.76 (0.62, 0.93)      **0.009**
  *OAS2* (12)           rs13311        CC            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       CA       1.03 (0.80, 1.33)     0.808      0.78 (0.44, 1.38)    0.403    1.11 (0.84, 1.47)        0.473
                                       AA       3.27 (1.55, 7.55)   **0.003**            --             --     3.42 (1.61, 7.93)      **0.002**
                                    trend (A)   1.21 (0.97, 1.51)     0.091      0.78 (0.44, 1.38)    0.402    1.32 (1.03, 1.68)        0.026
  *TLR4* (9)           rs10759932      TT            1 (Ref)            --            1 (Ref)           --          1 (Ref)               --
                                       TC       0.79 (0.60, 1.05)     0.111      0.75 (0.41, 1.38)    0.360    0.81 (0.59, 1.11)        0.190
                                       CC       4.13 (1.63, 12.6)   **0.005**    5.67 (1.36, 38.68)   0.033    3.48 (1.05, 15.66)       0.061
                                    trend (C)   1.03 (0.81, 1.31)     0.827      1.23 (0.77, 1.99)    0.388    0.97 (0.73, 1.28)        0.822

Odds ratios (OR), 95% confidence intervals (95% CI) and P-values obtained using the unconditional multivariate logistic model adjusted on age, institution, and genetic ancestry (first Principal Component) for SNPs that had at least one of the three tests (heterozygous, rare homozygous or trend) with a P-value below 0.01.

Stratifying on ethnicity shows that most of the SNPs associated with the pathway, sub-pathways, and SNPs in the whole sample are also detected in Caucasians, which represents more than 80% of the sample, but not in African Americans ([Tables 2](#pone-0051680-t002){ref-type="table"}, [3](#pone-0051680-t003){ref-type="table"}, and [Table S2](#pone.0051680.s002){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this integrative analysis of the association of advanced prostate cancer risk with candidate genes involved in innate immunity and inflammation, we studied 320 SNPs and their joint effects across genes and sub-pathways. Taken as a whole, the overall innate immunity and inflammation pathway seems to be involved in advanced prostate cancer, but the individual elements of this association are not clear. Indeed, the whole set of 320 SNPs is significantly associated with advanced prostate cancer risk. However, none of the other evaluated associations with sub-pathways, genes, or individual SNPs were significant, when correcting for multiple testing by making permutation based estimates of the family-wise error rate.

Nonetheless, our results suggest that the extracellular pattern recognition, the intracellular antiviral molecules, and the eicosanoid signaling (ie, *COX-2*) could be components that play a potential role in advanced prostate cancer risk. Within those sub-pathways, 5 genes (*TLR1*, *TLR6*, *OAS1*, *OAS2*, and *COX-2*) were nominally associated with advanced prostate cancer risk. Moreover, these genes harbor several SNPs nominally associated with advanced prostate cancer risk.

*TLR1* and *TLR6* encode members of the toll-like receptor family. Their role is to recognize molecular patterns associated to infectious pathogens. Both are highly conserved from *Drosophilia* to humans and share structural and functional similarities. Moreover, TLR1 and TLR6 also share the ability to form a heterodimer with TLR2 to recognize peptidoglycan and lipoproteins on pathogens. TLR1 is specialized in the recognition of gram-positive bacteria. Several studies have reported prostate cancer associations with members of the toll-like receptor family [@pone.0051680-Chen1], [@pone.0051680-Sun2], [@pone.0051680-Zheng1]. In particular Sun et al. [@pone.0051680-Sun2] observed multiple SNPs in strong linkage disequilibrium located on *TLR1*, *TLR6*, and *TLR10* associated with prostate cancer. In our dataset, we observed the same association with rs5743551on *TLR1* and rs5743795 on *TLR6*.

*OAS1* and *OAS2* encode for two enzymes of the 2--5A synthetase family, involved in the innate immune response to viral infections. These molecules are induced by interferons and activate RNase L (product of *RNASEL*) which degrades viral RNA and inhibits replication. Recently, Molinaro et al. [@pone.0051680-Molinaro1] showed that RNA fractions of prostate cancer cell lines are able to bind and activate OAS molecules, whereas RNA fractions of normal prostate epithelial cells cannot. Also, viral infections, sexually transmitted diseases [@pone.0051680-Baker1], [@pone.0051680-Grinstein1], [@pone.0051680-Hayes1], [@pone.0051680-Hoffman1], [@pone.0051680-Samanta1], [@pone.0051680-Taylor1], and infections with *Propionibacterium acnes*, a gram positive bacterium, [@pone.0051680-Cohen1], [@pone.0051680-Lee1] have been suggested as triggers in prostate cancer. These infectious agents may be cleared after the acute infection. Nonetheless, these agents could possibly induce carcinogenesis through the activation of a chronic inflammatory response [@pone.0051680-Platz1]. Only one study of the association between prostate cancer and *OAS1* was done on a smaller sample size and 3 SNPs different from our selection where an association with rs2660 was found [@pone.0051680-Mandal1].

*COX-2* encodes for the enzyme cyclooxygenase-2 (COX-2). COX-2 converts arachidonic acid to prostaglandin H2, which is a precursor for other tissue-specific inflammatory molecules (prostanoids). COX-2 was found to be overexpressed in prostate cancer tissue compared to the surrounding normal prostate tissue [@pone.0051680-Gupta1], [@pone.0051680-Kirschenbaum1], [@pone.0051680-Lee2]. The association of genetic variants with prostate cancer risk has also been outlined in previous studies, including in the same dataset [@pone.0051680-Cheng1], [@pone.0051680-Panguluri1], [@pone.0051680-Reese1], [@pone.0051680-Shahedi1], [@pone.0051680-Hedelin1]. However, reports on the association between elevated expression of COX-2 in prostate cancer tissues and high Gleason score and recurrence of the disease have mixed results [@pone.0051680-Cohen2], [@pone.0051680-Wang2], [@pone.0051680-Zha1].

Our results are concordant with those reported by Zheng et al. [@pone.0051680-Zheng2] who studied 9,275 SNPs in 1,086 inflammation genes using 200 familial cases and 200 controls of Swedish origin. They observed a significant enrichment in the number of nominal associations observed, suggesting the role of multiple genes with modest effects. However, by using the SKAT, our study is the first analysis of SNP sets pooled across genes and sub-pathways within the innate immunity and inflammation pathway.

None of the SNPs or genes included in our study was reported in any of the genome-wide association studies of prostate cancer listed in the Catalog of Genome-Wide Association studies [@pone.0051680-Hindorff1].

Nonetheless, our study has several limitations. First, the limited sample size, and thus limited power, could explain why the association with the whole set of genes is significant while none of the associations with the sub-pathways, genes, or SNPs are significant after correcting for multiple testing. With this sample, the minimum (or maximum for protective) odds ratio detectable with a power of 80% varies between 1.5 (or 0.67) and 2.19 (or 0.46) when the MAF varies between 0.5 and 0.05. Moreover, the limited sample size does not allow evaluating potential heterogeneous effects of variants by ethnicity or other covariates. Second, although a more stringent selection of cases would better describe the role of the innate immunity and inflammation pathway in advanced prostate cancer, it would decrease the sample size --and consequently the power-- drastically. Third, our selection of SNPs cannot exclude the possibility for rare functional variants in these candidate genes to play a role in advanced prostate cancer risk. Third, although the SKAT method provides an ideal framework to test for association with sets of potentially correlated SNPs, it does not measure the increase in risk associated with variants in the set of SNPs.

In conclusion, this study furthers research into prostate cancer genetics by studying SNPs in a candidate pathway at multiple levels of information: whole pathway, sub-pathways, genes, and SNPs. Our results suggest that although it may not be central in the etiology of advanced prostate cancer, the innate immunity and inflammation pathway could play a role in prostate cancer through different genetic variants.

Supporting Information {#s5}
======================

###### 

Description of the 320 single nucleotide polymorphisms analyzed. A1: Minor (rarer) allele; A2: Other (frequent) allele; A1A1: Rarer homozygous genotype; A1A2: Heterozygous genotype; A2A2: Frequent homozygous genotype; MAF: Minor allele frequency; P~Hardy-Weinberg~: Hardy-Weinberg proportion adequacy test (chi-square test).

(XLSX)

###### 

Click here for additional data file.

###### 

Association of all SNPs analyzed with advanced prostate cancer risk. The next 3 Excel sheets contain the results of the analyses for the whole sample (Overall) and stratified by ethnicities: African Americans and Caucasians. OR: Odds Ratio; 95% CI: 95% confidence interval; P-value: P-value of the Wald test of association of the heterozygote or rare homozygote genotypes compared to the common homozygote genotype or P-value of the allelic trend test.

(XLSX)

###### 

Click here for additional data file.
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